Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415354 | 0.88 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL2413229 | 0.87 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL21067784 | 0.87 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL2418015 | 0.87 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL2417758 | 0.87 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL2420213 | 0.86 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL2415627 | 0.86 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL2422275 | 0.85 | ESR2 (0.88) | ESR2ESR1 | |
| SCHEMBL2418936 | 0.84 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL2418441 | 0.84 | ESR2 (1.00) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257264-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | claimed |
| US-20080161372-A1 | Methods for the Treatment of Hypertension | MERCK & CO., INC. | 2008-07-03 | — | — | US | claimed |
| EP-1734960-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION | Merck & Co., Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| US-7087599-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-08-08 | — | — | US | claimed |
| WO-2005099704-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | claimed |
| EP-1257264-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | claimed |
| US-20050137192-A1 | Estrogen receptor modulators | PARKER DANN R JR (US) | 2005-06-23 | — | — | US | claimed |
| US-20030027840-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2003-02-06 | — | — | US | claimed |
| EP-1257264-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2002-11-20 | — | — | EP | claimed |
| WO-2001082923-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2001-11-08 | — | — | WO | claimed |
| EP-1257264-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20080161372-A1 | Methods for the Treatment of Hypertension | MERCK & CO., INC. | 2008-07-03 | — | — | US | disclosed |
| EP-1734960-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION | Merck & Co., Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005099704-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027840-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | ESR2 2/4885ESR1 5/4885 |
| US-20050137192-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | ESR2 2/4885ESR1 5/4885 |
| US-20080161372-A1 | Methods for the Treatment of Hypertension | EDNRA, GPER1, EDNRB | ESR2 8/4885ESR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.